AIM ImmunoTech reports Q2 2026 net loss of $3.8M; completes Phase 2 pancreatic cancer enrollment

AIM ImmunoTech Inc.

2026-Q2 EPS reported -$0.96 vs consensus -$0.17 ▼ miss (-459.1%)

Q2 2026 net loss of $3.8M ($0.43/share) vs $2.8M ($3.68/share) in Q2 2025; cash $9.9M vs $3.0M at year-end 2025.
Completed enrollment and Ampligen dosing in Phase 2 DURIPANC trial (metastatic pancreatic cancer) with AstraZeneca's Imfinzi.
Engaged Thermo Fisher's PPD for Phase 3 study design; anticipates DURIPANC clinical benefit data Q1 2027, OS data Q3 2027.
Ampligen showed median OS 34.8 months vs 12.5 months historical controls in Dutch Named Patient Program.
Regained full compliance with NYSE American listing standards; planning Ebola virus disease initiatives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.